For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8-12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
Scope of the Report:
The global average price of Rivaroxaban is in the decreasing trend, from 5.62 USD/Unit in 2011 to 5.34 USD/Unit in 2015. With the situation of global economy, prices will be in slowly decreasing trend in the following five years.
Bayer is the only supplier of Rivaroxaban enjoying production market share100% in 2015 and it will still in this situation until 2023.
The worldwide market for Rivaroxaban is expected to grow at a CAGR of roughly 9.4% over the next five years, will reach 10100 million US$ in 2024, from 5860 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Rivaroxaban in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- 2.5 mg
- 10 mg
- 15 mg
- 20 mg
Market Segment by Applications, can be divided into
- Acute Coronary Syndrome (ACS)
- Venous Thromboembolism (VTE)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Rivaroxaban product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Rivaroxaban, with price, sales, revenue and global market share of Rivaroxaban in 2017 and 2018.
Chapter 3, the Rivaroxaban competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Rivaroxaban breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Rivaroxaban market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Rivaroxaban sales channel, distributors, customers, research findings and conclusion, appendix and data source.